title: Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus.
abstract: BACKGROUND
  Induction chemoradiotherapy followed by esophagectomy may provide results superior to those of single-modality treatment in patients with esophageal cancer. The purpose of this study was to review our experience with this approach for esophageal cancer.
  
  
  METHODS
  From 1988 to 1996, 166 consecutive patients with esophageal cancer were evaluated; 66 entered a protocol of chemotherapy (5-fluorouracil, cisplatin) concurrent with radiation (45 Gy) followed by esophagectomy. Fifty-four patients completed the protocol.
  
  
  RESULTS
  Toxicity associated with induction chemoradiotherapy was minimal. The actuarial survival at 12, 24, and 36 months was 59%, 42%, and 32%, respectively. The pathologic complete response (pCR) rate was 41%, with 12-, 24-, and 36-month survivals of 77%, 50%, and 45%, whereas non-pCR patients had survivals of 46%, 35%, and 23%. The difference in survival between pCR and non-pCR patients was not significant (p = 0.13), but the difference in recurrence-free survival was significant (p = 0.007).
  
  
  CONCLUSIONS
  This well-tolerated protocol resulted in a high pCR. Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status.
authors.affiliation: Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill 27599-7065, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Jones
authors.forename: F C
authors.initials: FC
authors.lastname: Detterbeck
authors.forename: T M
authors.initials: TM
authors.lastname: Egan
authors.forename: L A
authors.initials: LA
authors.lastname: Parker
authors.forename: S A
authors.initials: SA
authors.lastname: Bernard
authors.forename: J E
authors.initials: JE
authors.lastname: Tepper
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016629:Esophagectomy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D016019:Survival Analysis
chemical_list: D002945:Cisplatin; D005472:Fluorouracil